[1]鞠铭伊,毕 佳,卫 倩,等.肝癌免疫相关预后标志物的分析[J].郑州大学学报(医学版),2020,(06):779-785.[doi:10.13705/j.issn.1671-6825.2019.12.104]
 JU Mingyi,BI Jia,WEI Qian,et al.Analysis of immune-related prognostic markers of liver cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2020,(06):779-785.[doi:10.13705/j.issn.1671-6825.2019.12.104]
点击复制

肝癌免疫相关预后标志物的分析()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2020年06期
页码:
779-785
栏目:
论著
出版日期:
2020-11-20

文章信息/Info

Title:
Analysis of immune-related prognostic markers of liver cancer
作者:
鞠铭伊毕 佳卫 倩江龙洋齐傲霜宋昕樾关秋彤张 明赵 琳魏敏杰孙明立
中国医科大学药学院药理学教研室; 辽宁省分子靶向抗肿瘤药物药理学研究与评价实验室; 辽宁省肿瘤免疫多肽药物工程研究中心 沈阳 110122
Author(s):
JU MingyiBI JiaWEI QianJIANG LongyangQI AoshuangSONG XinyueGUAN QiutongZHANG MingZHAO LinWEI MinjieSUN Mingli
Department of Pharmacology,School of Pharmacy China Medical University; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center,Shenyang 110122
关键词:
癌症基因组图谱 基因表达汇编 人类蛋白质图谱 肝癌 免疫 预后标志物
Keywords:
the cancer genome atlas gene expression omnibus human protein atlas liver cancer immune prognosis biomarker
分类号:
R735.7
DOI:
10.13705/j.issn.1671-6825.2019.12.104
摘要:
目的:筛选与免疫相关的、稳定的肝癌预后标志物。方法:从癌症基因组图谱(TCGA)数据库中下载肝癌患者的相关数据,筛选出差异表达的肝癌免疫相关基因。通过对这些基因进行单因素、多因素分析,筛选肝癌预后标志物。用 DAVID在线工具进行GO和KEGG 富集途径分析。利用HPA数据库和GSE14520对结果进行验证。结果:本研究获得了一个由9个与肝癌免疫相关的基因(PSMD14、STC2、SPP1、ISG20L2、MAPT、NR6A1、PSME3、HSP90AA1和CSPG5)组成的肝癌预后标志物,这一标志物与肝癌患者的总生存期显著相关(P<0.001)。结论:由PSMD14、STC2、SPP1、ISG20L2、MAPT、NR6A1、PSME3、HSP90AA1和CSPG5组成的标志物可作为评估肝癌预后的分子标志物,为肝癌的有效免疫治疗策略提供了新的见解。
Abstract:
Aim:To mine a prognostic biomarker consisted of immune-related genes for liver cancer.Methods: We selected immune-related differentially expressed genes from gene expression data of liver cancer patients in the cancer genome atlas(TCGA)database.To excavate prognosis biomarkers,we used univariate and multivariate Cox regression analysis.Visualization andintegrated discovery(DAVID)database was used to enrich biological themes on GO terms and on the Kyoto encyclopedia of genes and genomes(KEGG)pathway maps.Human protein atlas(HPA)database and GSE14520 were utilized to testify the stable of our results.Results: In our study,we identified and validated a biomarker consisted of 9 immune-related genes(PSMD14,STC2,SPP1,ISG20L2,MAPT,NR6A1,PSME3,HSP90AA1 and CSPG5)that could be useful for outlining overall survival(OS)of patients with liver cancer(P<0.001).Conclusion: The biomarker consisted of PSMD14,STC2,SPP1,ISG20L2,MAPT,NR6A1,PSME3,HSP90AA1 and CSPG5 is significantly associated with prognosis of liver cancer.Our findings have given novel insights of new immunotherapies for liver cancer.

参考文献/References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394
[2] 刘亮,刘江惠,陈乐彤,等.青蒿琥酯对肝癌细胞生长的抑制作用及其机制[J].解放军医学杂志,2018,43(07):594
[3] EL-KHOUEIRY AB,SANGRO B,YAU T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(188):2492
[4] MANDAL R,TA C.Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy[J].Cancer Discov,2016,6(7):703
[5] ZHU R,LIU YS,ZHOU HH,et al.Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma[J].Cancer letters,2018.418:125
[6] LV J,ZHANG S,WU H,et al.Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2[J].Cancer Lett,2020,469:22
[7] WU F,LI TY,SU SC,et al.STC2 as a novel mediator for Mus81-dependent proliferation and survival in hepatocellular carcinoma[J].Cancer Lett,2017,388:177
[8] 李志鹏,杨颖,贾春丽,等.STC2在肝细胞癌组织中的表达及临床意义[J].中华全科医学,2018,16(6):868
[9] CHENG H,WU Z,WU C,et al.Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells[J].Mater Sci Eng C Mater Biol Appl,2018,83:210
[10]查斌山,刘开坤,刘悦芳,等.SPP-1、GDF-15和CXCL-1在人小肝癌中表达的初步研究[J].武汉大学学报(医学版),2009,30(1):38
[11]CHEN PF,LI QH,ZENG LR,et al.A 4-gene prognostic signature predicting survival in hepatocellular carcinoma[J].J Cell Biochem,2019,120(6):9117
[12]ZHANG Z,LI J,HE T,et al.Two predictive precision medicine tools for hepatocellular carcinoma[J].Cancer cell international,2019,19:290
[13]SONG W,GUO C,CHEN JX,et al.Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1[J].Exp Biol Med(Maywood),2019,244(16):1409
[14]LIU C,YANG J,WU H,et al.Downregulated miR-585-3p promotes cell growth and proliferation in colon cancer by upregulating[J].OncoTargets and therapy,2019,12:6525
[15]YU L,LI JJ,LIANG XL,et al.PSME3 promotes TGFB1 Secretion by pancreatic cancer cells to induce pancreatic stellate cell proliferation[J].J Cancer,2019,10(9):2128
[16]TORAIH EA,ALREFAI HG,HUSSEIN MH,et al.Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: a pilot study[J].Clin Biochem,2019,63:10

备注/Memo

备注/Memo:
【基金项目】国家自然科学基金项目(U1608281); 沈阳市科技计划项目(19-109-4-09)
【作者简介】赵琳,通信作者,女,1979年10月生,博士,教授,研究方向:基于多组学和大数据分析的肿瘤微环境与异质性,E-mail:zl_cmu@163.com
更新日期/Last Update: 2020-11-20